0001213900-24-032951.txt : 20240415 0001213900-24-032951.hdr.sgml : 20240415 20240415160515 ACCESSION NUMBER: 0001213900-24-032951 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20240409 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240415 DATE AS OF CHANGE: 20240415 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Augmedix, Inc. CENTRAL INDEX KEY: 0001769804 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-BUSINESS SERVICES, NEC [7389] ORGANIZATION NAME: 07 Trade & Services IRS NUMBER: 833299164 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40890 FILM NUMBER: 24844669 BUSINESS ADDRESS: STREET 1: 111 SUTTER STREET, SUITE 1300 CITY: SAN FRANCISCO STATE: CA ZIP: 94104 BUSINESS PHONE: 561-989-2208 MAIL ADDRESS: STREET 1: 111 SUTTER STREET, SUITE 1300 CITY: SAN FRANCISCO STATE: CA ZIP: 94104 FORMER COMPANY: FORMER CONFORMED NAME: Malo Holdings Corp DATE OF NAME CHANGE: 20190305 8-K 1 ea0203920-8k_augmedix.htm FORM 8-K
false 0001769804 0001769804 2024-04-09 2024-04-09 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): April 9, 2024

AUGMEDIX, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   001-40890   83-3299164

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(I.R.S. Employer

Identification No.)

 

111 Sutter Street, Suite 1300, San Francisco, California 94104

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (888) 669-4885

N/A

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, $0.0001 par value per share   AUGX   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

Item 1.01. Entry into a Material Definitive Agreement

On April 9, 2024 (the “Effective Date”), Augmedix Operating Corp., a Delaware corporation (f/k/a Augmedix, Inc., the “Company”), and subsidiary of Augmedix, Inc., entered into a Seventh Omnibus Amendment (the “Amendment”) with Dignity Health (“DH”), Dignity Health Medical Foundation (“DHMF”), and Pacific Central Coast Health Centers (“PHC”) to amend the statements of work (the “SOWs”) previously entered into between the Company and each of DH, DHMF and PHC pursuant to a Services Agreement, dated September 1, 2015, by and between the Company and CommonSpirit Health (f/k/a Catholic Health Initiative) (“CommonSpirit”), as successor-in-interest to Dignity Health (the “Agreement”). The Amendment extends the term of the SOWs through June 30, 2024 and memorializes the intent of the Company and CommonSpirit to negotiate in good faith a new enterprise-wide agreement.

A copy of the Amendment is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference. The foregoing description of the Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of the Amendment.

Item 9.01. Financial Statements and Exhibits.

(d)Exhibits.

 

 Exhibit 
No.

   Description
10.1   Seventh Omnibus Amendment, entered into on April 9, 2024, by and among Augmedix Operating Corp. f/k/a Augmedix, Inc., Dignity Health, Dignity Health Medical Foundation, and Pacific Central Coast Health Centers.
104   Cover Page Interactive Data File--the cover page XBRL tags are embedded within the Inline XBRL document.

 

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

AUGMEDIX, INC.
     
Dated: April 15, 2024 By: /s/ Paul Ginocchio
    Paul Ginocchio
    Chief Financial Officer

 

 

 EX-10.1 2 ea0203920ex10-1_augmedix.htm SEVENTH OMNIBUS AMENDMENT, ENTERED INTO ON APRIL 9, 2024, BY AND AMONG AUGMEDIX OPERATING CORP. F/K/A AUGMEDIX, INC., DIGNITY HEALTH, DIGNITY HEALTH MEDICAL FOUNDATION, AND PACIFIC CENTRAL COAST HEALTH CENTERS.

 

Exhibit 10.1

 

SEVENTH OMNIBUS AMENDMENT

 

This Seventh Omnibus Amendment (“Seventh Omnibus Amendment”) is made and entered into as of April 1, 2024 (“Amendment Effective Date”), by and between, on the one hand, Augmedix Operating Corp. f/k/a Augmedix, Inc. (“Augmedix”) and, on the other hand, Dignity Health (“DH”), Dignity Health Medical Foundation (“DHMF”), and Pacific Central Coast Health Centers (“PHC” and, together with the DH and DHMF, the “Client”), and amends:

 

(1)That certain Amended and Restated Statement of Work, dated January 24, 2019, as amended, by and between DH and Augmedix (the “DH-SOW No. 1”); and

 

(2)That certain Statement of Work No. 2, dated March 2, 2020, as amended, by and between DH and Augmedix (the “DH-SOW No. 2”); and

 

(3)That certain Statement of Work, dated July 3, 2016, as amended, by and between DHMF and Augmedix (the “DHMF-SOW”); and

 

(4)That certain Statement of Work, dated January 26, 2016, as amended, by and between PHC and Augmedix (the “PHC-SOW” and, together with the DH-SOW No. 1, DH-SOW No. 2, and DHMF-SOW, the “Dignity SOW(s)”).

 

WHEREAS, Dignity Health (for itself and on behalf of its affiliates) and Augmedix entered into that certain Services Agreement, dated September 1, 2015 (the “Agreement”).

 

WHEREAS, Dignity Health has affiliated with Catholic Health Initiatives, which has been renamed CommonSpirit Health (f/k/a Catholic Health Initiative), a Colorado non-profit corporation (“CommonSpirit”), and become the parent company of Dignity Health; and

 

WHEREAS, CommonSpirit Health, Dignity Health, and Augmedix agreed to assign the Agreement to CommonSpirit Health, effective October 20, 2022, so that CommonSpirit and its affiliates may order products, services, and subscriptions from Augmedix through the Agreement.

 

NOW, THEREFORE, in consideration of the mutual benefits and promises between the parties, the sufficiency of which each party hereby acknowledges, the Dignity SOWs are hereby amended as follows:

 

1.                Term. Notwithstanding anything to the contrary in the Dignity SOWs, this Seventh Omnibus Amendment extends the Term of the Dignity SOWs through and including June 30, 2024, unless earlier terminated in accordance with the Agreement.

 

2.                CommonSpirit Enterprise Agreement. Notwithstanding the extension of the Dignity SOWs through and including June 30, 2024, the parties acknowledge that Augmedix and CommonSpirit intend to discuss and negotiate in good faith the terms and conditions of an enterprise wide CommonSpirit agreement for the provision of the Services to its member organizations. Upon execution of a definitive enterprise agreement between Augmedix and CommonSpirit, the Agreement and associated Dignity SOWs shall terminate and the enterprise agreement between Augmedix and CommonSpirit will govern Augmedix’s provision of the Services to all CommonSpirit member organizations, including DH, DHMF and PHC.

 

3.                General. Capitalized terms used but not otherwise defined herein shall have the same meaning as in the Dignity SOWs and the Agreement. This Seventh Omnibus Amendment is hereby incorporated into the Dignity SOWs by reference. Except as expressly amended herein, all other terms of the Dignity SOWs are hereby confirmed and remain in full force and effect. To the extent that there is any conflict between the terms of this Seventh Omnibus Amendment and those of the Agreement or the Dignity SOWs, the terms of this Seventh Omnibus Amendment shall control. This Seventh Omnibus Amendment may be executed in several counterparts, all of which taken together shall constitute one single agreement between the parties and any full and complete copy thereof shall constitute an original. When signed in pen ink, such documents may be delivered by facsimile transmission or by scanned email attachment, and said copies shall be treated in all respects as original.

 

 

 

AGREED AND ACCEPTED

 

DIGNITY HEALTH   AUGMEDIX Operating Corp. F/K/A Augedix Inc.
         
By /s/ Ian Vallely   By /s/ Manny Krakaris
         
Name Ian Vallely   Name Manny Krakaris
         
Title VP, CIO Physician Enterprise   Title CEO
         
Date April 9, 2024   Date April 9, 2024

 

DIGNITY HEALTH MEDICAL FOUNDATION  
     
By /s/ Ian Vallely  
     
Name Ian Vallely  
     
Title VP, CIO Physician Enterprise  
     
Date April 9, 2024  
     
PACIFIC CENTRAL COAST HEALTH CENTERS  
     
By /s/ Ian Vallely  
     
Name Ian Vallely  
     
Title VP, CIO Physician Enterprise  
     
Date April 9, 2024  

 

 

 EX-101.SCH 3 augx-20240409.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 augx-20240409_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 augx-20240409_pre.xml XBRL PRESENTATION FILE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Cover
Apr. 09, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Apr. 09, 2024
Entity File Number 001-40890
Entity Registrant Name AUGMEDIX, INC.
Entity Central Index Key 0001769804
Entity Tax Identification Number 83-3299164
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 111 Sutter Street
Entity Address, Address Line Two Suite 1300
Entity Address, City or Town San Francisco
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94104
City Area Code (888)
Local Phone Number 669-4885
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.0001 par value per share
Trading Symbol AUGX
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.u1 html 1 24 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://augmedix.com/role/Cover Cover Cover 1 false false All Reports Book All Reports augx-20240409.xsd augx-20240409_lab.xml augx-20240409_pre.xml ea0203920-8k_augmedix.htm http://xbrl.sec.gov/dei/2024 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "ea0203920-8k_augmedix.htm": { "nsprefix": "AUGX", "nsuri": "http://augmedix.com/20240409", "dts": { "schema": { "local": [ "augx-20240409.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" ] }, "labelLink": { "local": [ "augx-20240409_lab.xml" ] }, "presentationLink": { "local": [ "augx-20240409_pre.xml" ] }, "inline": { "local": [ "ea0203920-8k_augmedix.htm" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2024": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2024": 24 }, "report": { "R1": { "role": "http://augmedix.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-04-09", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "ea0203920-8k_augmedix.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-04-09", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "ea0203920-8k_augmedix.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentDescription", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AnnualInformationForm", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CountryRegion", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAccountingStandard", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAnnualReport", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodStartDate", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentRegistrationStatement", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyReport", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine3", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCountry", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityExTransitionPeriod", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPrimarySicNumber", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityVoluntaryFilers", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Extension", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "NoTradingSymbolFlag", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementTenderOffer", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12gTitle", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityReportingObligation", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SolicitingMaterial", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "WrittenCommunications", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14a", "Subsection": "12" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 15 0001213900-24-032951-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213900-24-032951-xbrl.zip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end XML 17 ea0203920-8k_augmedix_htm.xml IDEA: XBRL DOCUMENT 0001769804 2024-04-09 2024-04-09 iso4217:USD shares iso4217:USD shares false 0001769804 8-K 2024-04-09 AUGMEDIX, INC. DE 001-40890 83-3299164 111 Sutter Street Suite 1300 San Francisco CA 94104 (888) 669-4885 false false false false Common Stock, $0.0001 par value per share AUGX NASDAQ true false